{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:36:30Z","timestamp":1790825790125,"version":"4.1.0"},"reference-count":45,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["TTU 09.918"],"award-info":[{"award-number":["TTU 09.918"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["GBi2S"],"award-info":[{"award-number":["GBi2S"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:p>\n            Antimicrobial resistance (AMR) represents an ever increasing threat to the health care system. Even recently licensed drugs are often not efficient for the treatment of infections caused by Gram-negative bacteria, like\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            , a causative agent of lung infections. To address this unmet medical need, innovative antibiotics, which possess a new mode of action, need to be developed. Here, the antibiogram of clinical isolates derived from cystic fibrosis patients was generated and new bicyclic heptapeptides, which inhibit the outer membrane protein BamA, exhibited strong activity, also against multidrug-resistant isolates.\n          <\/jats:p>","DOI":"10.1128\/spectrum.04437-22","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T14:01:52Z","timestamp":1674568912000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":34,"title":["Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Cefiderocol, and Novel Darobactin Analogs against Multidrug-Resistant Pseudomonas aeruginosa Isolates from Pediatric and Adolescent Cystic Fibrosis Patients"],"prefix":"10.1128","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1024-1567","authenticated-orcid":true,"given":"Michael","family":"Marner","sequence":"first","affiliation":[{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Bioresources, Giessen, Germany"},{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3311-8254","authenticated-orcid":false,"given":"Laura","family":"Kolberg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Horst","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, LMU Munich, Munich, Germany"},{"name":"Institute for Medical Information Processing, Biometry, and Epidemiology \u2013 IBE, LMU Munich, Munich, Germany"},{"name":"Pettenkofer School of Public Health, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"B\u00f6hringer","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"H\u00fcbner","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, LMU Munich, Munich, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I Dewa M.","family":"Kresna","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ute","family":"Mettal","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Meyer-B\u00fchn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Mihajlovic","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Bioresources, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kappler","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9947-8079","authenticated-orcid":true,"given":"Till F.","family":"Sch\u00e4berle","sequence":"additional","affiliation":[{"name":"Fraunhofer Institute for Molecular Biology and Applied Ecology (IME), Branch for Bioresources, Giessen, Germany"},{"name":"Justus-Liebig-University of Giessen, Giessen, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8411-1071","authenticated-orcid":false,"given":"Ulrich","family":"von Both","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dr. von Hauner Children\u2019s Hospital, University Hospital, LMU Munich, Munich, Germany"},{"name":"Pettenkofer School of Public Health, Munich, Germany"},{"name":"German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","volume-title":"Reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, 2021.","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. 2021. Reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, 2021. (WHO\/MHP\/HPS\/EML\/2021.04). World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_4_3_2","volume-title":"Antimicrobial resistance: global report on surveillance.","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. 2014. Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_4_4_2","volume-title":"Global action plan on antimicrobial resistance. WHO Report 2015.","author":"World Health Organization","year":"2015","unstructured":"World Health Organization. 2015. Global action plan on antimicrobial resistance. WHO Report 2015. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02724-0"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-018-0125-x"},{"key":"e_1_3_4_8_2","volume-title":"Tackling drug-resistant infections globally: final report and recommendations.","author":"Review on Antimicrobial Resistance","year":"2016","unstructured":"Review on Antimicrobial Resistance. 2016. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance, London, United Kingdom."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.12.018"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902734116"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00138-18"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10127"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1515\/labmed-2014-0004"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00591-2"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2449"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz640"},{"key":"e_1_3_4_18_2","first-page":"479","article-title":"Ceftazidime-avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections","volume":"41","author":"Mosley JF","year":"2016","unstructured":"Mosley JF, II, Smith LL, Parke CK, Brown JA, Wilson AL, Gibbs LV. 2016. Ceftazidime-avibactam (Avycaz): for the treatment of complicated intra-abdominal and urinary tract infections. P T 41:479\u2013483.","journal-title":"P T"},{"key":"e_1_3_4_19_2","first-page":"110","article-title":"Meropenem-vaborbactam (Vabomere\u2122): another option for carbapenem-resistant enterobacteriaceae","volume":"44","author":"Lee Y","year":"2019","unstructured":"Lee Y, Kim J, Trinh S. 2019. Meropenem-vaborbactam (Vabomere\u2122): another option for carbapenem-resistant enterobacteriaceae. P T 44:110\u2013113.","journal-title":"P T"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2476"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz823"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1791-1"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-10-r90"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01535-21"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1039\/d1sc02725e"},{"key":"e_1_3_4_26_2","unstructured":"European Medicines Agency. 2021. Zerbaxa - EMEA\/H\/C\/003772 - IAIN\/0034. European Medicines Agency Amsterdam Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zerbaxa#authorisation-details-section."},{"key":"e_1_3_4_27_2","unstructured":"European Medicines Agency. 2022. Fetcroja-EMEA\/H\/C\/004829-II\/0006\/G. European Medicines Agency Amsterdam Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fetcroja."},{"key":"e_1_3_4_28_2","unstructured":"European Medicines Agency. 2022. Zavicefta - EMEA\/H\/C\/004027 - IB\/0029. European Medicines Agency Amsterdam Netherlands. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zavicefta."},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03455-w"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040377"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymben.2021.04.007"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.01026-20"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00286-6"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04405-14"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky363"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060723"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.04.016"},{"key":"e_1_3_4_38_2","unstructured":"Klinikum der Universit\u00e4t M\u00fcnchen Lungenerkrankungen-Christiane Herzog Ambulanz. Klinikum der Universit\u00e4t M\u00fcnchen Lungenerkrankungen-Christiane Herzog Ambulanz. 2018. http:\/\/www.klinikum.uni-muenchen.de\/Kinderklinik-und-Kinderpoliklinik-im-Dr-von-Haunerschen-Kinderspital\/de\/ambulanzen\/lungenerkrankungen-christiane-herzog-ambulanz\/index.html. Accessed 24 August 2022."},{"key":"e_1_3_4_39_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2022. Breakpoint tables for interpretation of MICs and zone diameters: version 12.0. http:\/\/www.eucast.org. Accessed 20 June 2022."},{"key":"e_1_3_4_40_2","unstructured":"Liofilchem. 2017. Liofilchem ceftolozane-tazobactam MIC test strip technical sheet. Liofilchem Roseto degli Abruzzi Italy. http:\/\/www.liofilchem.net\/login.area.mic\/technical_sheets\/MTS42.pdf. Accessed 20 February 2022."},{"key":"e_1_3_4_41_2","unstructured":"Liofilchem. 2021. Liofilchem MTS TM cefiderocol 0.016-256: technical sheet. Liofilchem Roseto degli Abruzzi Italy. https:\/\/www.liofilchem.com\/images\/brochure\/mic_test_strip_patent\/MTS51.pdf. Accessed 20 June 2022."},{"key":"e_1_3_4_42_2","unstructured":"Liofilchem. 2020. Liofilchem drug specific supplement for MTS TM ceftazidime-avibactam. Liofilchem Roseto degli Abruzzi Italy. https:\/\/www.liofilchem.com\/images\/prodotti-usa\/FDA-MTS-CZA.pdf. Accessed 20 June 2022."},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jnatprod.0c00263"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202100644"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02479-21"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-4165(69)90353-5"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.04437-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.04437-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:51:15Z","timestamp":1676386275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.04437-22"}},"subtitle":[],"editor":[{"given":"Brian","family":"Conlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2,14]]}},"alternative-id":["10.1128\/spectrum.04437-22"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.04437-22","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"2022-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e04437-22"}}